Studies validating the prognostic accuracy of the tumor-node-metastases (TNM) classification
in patients with lung cancer treated by neoadjuvant therapy are scarce. Tumor regression, …

The tumor immune composition influences prognosis and treatment sensitivity in lung cancer.
The presence of effective adaptive immune responses is associated with increased clinical …

Despite known histological, biological, and clinical differences between lung adenocarcinoma
(LUAD) and squamous cell carcinoma (LUSC), relatively little is known about the spatial …

Background The response to neoadjuvant chemotherapy (NAC) differs substantially among
individual patients with non‐small cell lung cancer (NSCLC). Major pathological response (…

Background Brain metastases present a significant complication in lung cancer with an
unmet therapeutic need. Methods In this single-centre, retrospective study, we genotyped a …

Carbon-bound exogenous compounds, such as polycyclic aromatic hydrocarbons (PAHs),
tobacco-specific nitrosamines, aromatic amines, and organohalogens, are known to affect …

Molecular subtyping of lung squamous cell carcinoma (LUSC) has been performed at the
genomic, transcriptomic, and proteomic level. However, LUSC stratification based on tissue …

Background Adult-type diffuse gliomas, CNS WHO grade 4 are the most aggressive primary
brain tumors and represent a particular challenge for therapeutic intervention. Methods In a …

PD-L1 expression is the routine clinical biomarker for the selection of patients to receive
immunotherapy in non-small cell lung cancer (NSCLC). However, the application and best …

Rationale: Despite evidence suggesting that the tumor microenvironment (TME) in malignant
pleural mesothelioma (MPM) is linked with poor prognosis, there is a lack of studies that …